2021
The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial
Chouairi F, Fuery MA, Mullan CW, Caraballo C, Sen S, Maulion C, Wilkinson ST, Surti T, McCullough M, Miller PE, Pacor J, Leifer ES, Felker GM, Velazquez EJ, Fiuzat M, O'Connor CM, Januzzi JL, Desai NR, Ahmad T. The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial. Journal Of Cardiac Failure 2021, 27: 1359-1366. PMID: 34166799, DOI: 10.1016/j.cardfail.2021.06.008.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyReduced ejection fractionAmino-terminal pro-B-type natriuretic peptide levelsPro-B-type natriuretic peptide levelsGUIDE-IT trialNatriuretic peptide levelsHeart failureEjection fractionClinical outcomesPeptide levelsOptimal guideline-directed medical therapyCox proportional hazards regression modelingProportional hazards regression modelingImpact of depressionHistory of depressionCardiovascular deathCause hospitalizationCause mortalityOverall cohortMedical therapyAdverse outcomesTarget dosesPatientsMental healthTime pointsIntercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure
Fuery MA, Chouairi F, Januzzi JL, Moe GW, Caraballo C, McCullough M, Miller PE, Reinhardt SW, Clark K, Oseran A, Milner A, Pacor J, Kahn PA, Singh A, Ravindra N, Guha A, Vadlamani L, Kulkarni NS, Fiuzat M, Felker GM, O'Connor CM, Ahmad T, Ezekowitz J, Desai NR. Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure. JACC Heart Failure 2021, 9: 497-505. PMID: 33992564, DOI: 10.1016/j.jchf.2021.02.011.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyGDMT useCountry of enrollmentHeart failureMedical therapyHigher body mass indexKaplan-Meier survival estimatesGUIDE-IT trialHeart failure hospitalizationReduced ejection fractionLog-rank testingMineralocorticoid receptor antagonistsPrimary study endpointBody mass indexPatterns of careCare delivery structuresGUIDE-ITHF hospitalizationFailure hospitalizationUsual careEjection fractionStudy endpointBlack patientsClinical outcomesMass indexEffects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial
Chouairi F, Pacor J, Miller PE, Fuery MA, Caraballo C, Sen S, Leifer ES, Felker GM, Fiuzat M, O’Connor C, Januzzi JL, Friedman DJ, Desai NR, Ahmad T, Freeman JV. Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial. Mayo Clinic Proceedings Innovations Quality & Outcomes 2021, 5: 447-455. PMID: 33997640, PMCID: PMC8105522, DOI: 10.1016/j.mayocpiqo.2021.02.005.Peer-Reviewed Original ResearchNT-proBNP levelsReduced ejection fractionAtrial fibrillationHF hospitalizationHeart failureEjection fractionMedical therapyN-terminal pro-B-type natriuretic peptideOptimal guideline-directed medical therapyPro-B-type natriuretic peptideGuideline-directed medical therapyHigher NT-proBNP concentrationsHigher NT-proBNP levelsGUIDE-IT trialMedical therapy useHeart failure outcomesHeart Failure TrialPrevalent atrial fibrillationNT-proBNP concentrationsType natriuretic peptideEvidence-based therapiesCardiovascular deathAF patientsTherapy useFailure Trial
2020
Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure
Mezzacappa C, Ravindra NG, Caraballo C, Chouairi F, Miller PE, Clarke JD, Gruen J, Mori M, McCullough M, Mullan C, Geirsson A, Rogers JG, Anwer M, Desai N, Ahmad T. Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure. PLOS ONE 2020, 15: e0242928. PMID: 33270648, PMCID: PMC7714148, DOI: 10.1371/journal.pone.0242928.Peer-Reviewed Original ResearchConceptsClinical trialsVentricular assist deviceExclusion criteriaLVAD recipientsAssist deviceReal-world settingClinical implicationsClinical trial exclusion criteriaHeart failure clinical trialsEnd-stage renal diseaseEnd-stage heart failureReal-world registryRetrospective cohort studyLandmark clinical trialsStage renal diseaseTrial exclusion criteriaRisk of deathStage heart failureRespiratory failureCohort studyPatient characteristicsHeart failurePatient factorsRenal diseaseClinical outcomesCOVID-19 infections and outcomes in a live registry of heart failure patients across an integrated health care system
Caraballo C, McCullough M, Fuery MA, Chouairi F, Keating C, Ravindra NG, Miller PE, Malinis M, Kashyap N, Hsiao A, Wilson FP, Curtis JP, Grant M, Velazquez EJ, Desai NR, Ahmad T. COVID-19 infections and outcomes in a live registry of heart failure patients across an integrated health care system. PLOS ONE 2020, 15: e0238829. PMID: 32997657, PMCID: PMC7526909, DOI: 10.1371/journal.pone.0238829.Peer-Reviewed Original ResearchConceptsHeart failure patientsIntegrated health care systemHeart Failure RegistryHealth care systemFailure patientsCOVID-19 infectionCare systemCOVID-19SARS-CoV-2 infectionReal-time registryRenin-angiotensin blockersRetrospective chart reviewCoronary artery diseaseRisk of deathCOVID-19 testingAngiotensin blockersMultiple comorbiditiesRespiratory failureChart reviewSymptomatic patientsArtery diseaseHeart failureComorbid conditionsPatient mortalityClinical managementSex Differences in Patients Receiving Left Ventricular Assist Devices for End-Stage Heart Failure
Gruen J, Caraballo C, Miller PE, McCullough M, Mezzacappa C, Ravindra N, Mullan CW, Reinhardt SW, Mori M, Velazquez E, Geirsson A, Ahmad T, Desai NR. Sex Differences in Patients Receiving Left Ventricular Assist Devices for End-Stage Heart Failure. JACC Heart Failure 2020, 8: 770-779. PMID: 32653446, DOI: 10.1016/j.jchf.2020.04.015.Peer-Reviewed Original ResearchConceptsAdverse eventsVentricular assist deviceClinical outcomesPotential underuseHigh riskAssist deviceEnd-stage heartWomen 65 yearsRisk of deathContinuous-flow LVADYears of ageAdvanced treatment optionsSex differencesHeart transplantationMultivariable adjustmentHeart failureHeart transplantSimilar incidenceTreatment optionsSimilar riskSurvival analysisLVADPatientsDevice malfunctionWomenPsychiatric Comorbidity and Outcomes After Left Ventricular Assist Device Implantation for End-Stage Heart Failure
Mullan C, Caraballo C, Ravindra NG, Miller PE, McCullough M, Brown K, Aw TW, Gruen J, Clarke JD, Velazquez EJ, Geirsson A, Mori M, Desai NR, Ahmad T. Psychiatric Comorbidity and Outcomes After Left Ventricular Assist Device Implantation for End-Stage Heart Failure. JACC Heart Failure 2020, 8: 569-577. PMID: 32535119, DOI: 10.1016/j.jchf.2020.03.011.Peer-Reviewed Original ResearchConceptsPsychiatric comorbidityMajor psychiatric illnessNarcotic dependencePsychiatric illnessAdverse eventsHeart failureAlcohol abuseKansas City Cardiomyopathy Questionnaire scoreDrug useVentricular assist device implantationEnd-stage heart failureMechanically Assisted Circulatory SupportAssist device implantationEnd-stage heartRisk of rehospitalizationContinuous-flow LVADRisk of mortalityVulnerable patient populationVentricular assist deviceDevice-related infectionsInteragency RegistryLVAD recipientsSpecific psychiatric conditionsClinical outcomesPatient selectionClinical impact of concomitant tricuspid valve procedures during left ventricular assist device implantation
Mullan C, Caraballo C, Ravindra NG, Miller PE, Mori M, McCullough M, Clarke JD, Anwer M, Velazquez EJ, Geirsson A, Desai NR, Ahmad T. Clinical impact of concomitant tricuspid valve procedures during left ventricular assist device implantation. The Journal Of Heart And Lung Transplantation 2020, 39: 926-933. PMID: 32593561, DOI: 10.1016/j.healun.2020.05.007.Peer-Reviewed Original ResearchConceptsConcomitant tricuspid valve proceduresTricuspid valve proceduresSevere tricuspid regurgitationTricuspid regurgitationLVAD implantationValve proceduresLeft ventricular assist device implantationVentricular assist device implantationDegree of TREnd-stage heart failureAssist device implantationRisk of bleedingCases of mildContinuous-flow LVADVentricular assist deviceInteragency RegistryAdult patientsAdverse eventsSurvival benefitHeart failureClinical outcomesDevice implantationTR severityQOL outcomesClinical impactNeurohormonal Blockade and Clinical Outcomes in Patients With Heart Failure Supported by Left Ventricular Assist Devices
McCullough M, Caraballo C, Ravindra NG, Miller PE, Mezzacappa C, Levin A, Gruen J, Rodwin B, Reinhardt S, van Dijk D, Ali A, Ahmad T, Desai NR. Neurohormonal Blockade and Clinical Outcomes in Patients With Heart Failure Supported by Left Ventricular Assist Devices. JAMA Cardiology 2020, 5: 175-182. PMID: 31738366, PMCID: PMC6865330, DOI: 10.1001/jamacardio.2019.4965.Peer-Reviewed Original ResearchConceptsKansas City Cardiomyopathy Questionnaire scoreNeurohormonal blockadeAngiotensin receptor blockersVentricular assist deviceQuality of lifeMineralocorticoid antagonistsReceptor blockersHeart failureWalk testQuestionnaire scoresΒ-blockersEnzyme inhibitorsAssist deviceGuideline-directed medical therapyAngiotensin-converting enzyme inhibitorMechanically Assisted Circulatory SupportHeart failure regimenLeft ventricular assist deviceAdvanced heart failureRetrospective cohort analysisContinuous-flow LVADBetter survival rateOutcomes of interestInteragency RegistryTriple therapy
2019
Clinical Implications of the New York Heart Association Classification
Caraballo C, Desai NR, Mulder H, Alhanti B, Wilson FP, Fiuzat M, Felker GM, Piña IL, O'Connor CM, Lindenfeld J, Januzzi JL, Cohen LS, Ahmad T. Clinical Implications of the New York Heart Association Classification. Journal Of The American Heart Association 2019, 8: e014240. PMID: 31771438, PMCID: PMC6912957, DOI: 10.1161/jaha.119.014240.Peer-Reviewed Original ResearchConceptsNew York Heart Association classificationHF clinical trialsNYHA class IIVentricular ejection fractionGUIDE-ITHeart failureNYHA classWalk distanceEjection fractionRisk stratificationHF-ACTIONAssociation classificationClinical trialsMinute ventilation-carbon dioxide production relationshipKansas City Cardiomyopathy Questionnaire scoreClass IIMulticenter National InstituteNYHA class IIINT-proBNP levelsKaplan-Meier curvesLog-rank testClinical trial eligibilityWilcoxon rank sum testMaximal oxygen uptakeRank sum test